Pulished : October, 2018
ID: 31
Region: Global
Share on

Market Data Forecast report predicts that, the ‘Global Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market is predicted to reach $ 12.43 billion by 2020 with a CAGR of 9.00%

Pulished: October, 2018
ID: 31
Share on

The Global Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market report published by Market Data Forecast provides a detailed account of the Market Trends via Customized Research presented as Strategic Analyses, Company Profiles, and Competitive Landscape etc. According to the report, the Global Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market is estimated to reach $ 12.43 billion by 2020 from $ 8.08 billion in 2015 with a CAGR of 9.00%. The market is segmented based on medication (stimulants-amphetamines, methylphenidate, dextroamphetamine, and dexmethylphenidate & non-stimulants-atomoxetine, bupropion, and guanfacine), psychotherapy (behavior therapy, cognitive behavioral therapy, interpersonal psychotherapy, and family therapy), and education or training (parent management training, social skills training, and school-based interventions). Further the market is also geographically segmented into North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa.

Growth of attention deficit hyperactivity disorder (ADHD) therapeutics market is attributed to increasing advancements in medical field, growing number of researches in neurosciences, rising awareness about mental illness among people, and increasing focus of biotechnology & pharmaceutical companies to develop the innovative therapeutics for ADHD. However, high cost of the ADHD medications, improper reimbursement policies, and side effects related to ADHD medications (such as insomnia, anorexia, dizziness, headaches, and mood changes) are restraining the growth of global attention deficit hyperactivity disorder therapeutics market.

North America accounted for the largest market share of 36.0% of global attention deficit hyperactivity disorder (ADHD) therapeutics market in 2015, owing to availability of good healthcare infrastructure, presence of ongoing clinical trials, early approval of therapeutics in the U.S., increasing number of learning disability patients, growing adoption for ADHD therapeutics, existence of insurance policies for brain monitoring technologies, and government support for the technological advancements in neurosciences. Asia-Pacific region is estimated to be the fastest growing segment with a CAGR of 12.30% during forecast period 2015-2020. High growth of the market in this region is due to growing healthcare industry, increasing initiatives from government to provide better treatment solutions for mental illness conditions, growing focus of foreign pharmaceutical companies on Asian market, presence of huge population, and rising number of mental disorders.

The key players in global attention deficit hyperactivity disorder (ADHD) therapeutics market such as, Shire plc (Ireland), Neos Therapeutics, Inc. (U.S.), Eli Lilly and Company (U.S.), Pfizer Inc. (U.S.), Alcobra Ltd. (Israel), Supernus Pharmaceuticals, Inc. (U.S.), Noven Pharmaceuticals, Inc. (U.S.), Novartis AG (Switzerland), Johnson & Johnson (U.S.), and Curemark, LLC. (U.S.).

Browse through the full report at “http://www.marketdataforecast.com/market-reports/global-attention-deficit-hyperactivity-disorder-therapeutics-market-304/” and checkout our recent reports in the Pharmaceuticals category at “http://www.marketdataforecast.com/research-reports/healthcare/pharmaceuticals-1/”. For more insights and up-to-date industry news don’t forget subscribing to our newsletters.